troglitazone has been researched along with Colorectal Cancer in 9 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we identified a new mechanism for the anti-proliferation of HCT15 colorectal cancer cells by troglitazone (TRO)." | 7.71 | Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. ( Ahn, Y; Choi, KY; Kim, HI; Kim, JA; Oh, JW; Oh, SY; Park, KS, 2002) |
| " In this report, we show that ATF3 mRNA and protein expression are up-regulated in HCT-116 human colorectal cancer cells following treatment with NSAIDs, troglitazone, diallyl disulfide, and resveratrol." | 3.73 | The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). ( Alston-Mills, B; Bottone, FG; Eling, TE; Ishibashi, M; Kim, JS; Moon, Y, 2005) |
| "In this study, we identified a new mechanism for the anti-proliferation of HCT15 colorectal cancer cells by troglitazone (TRO)." | 3.71 | Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. ( Ahn, Y; Choi, KY; Kim, HI; Kim, JA; Oh, JW; Oh, SY; Park, KS, 2002) |
| "Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand that has pro-apoptotic activity in human colon cancer." | 1.32 | Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. ( Baek, SJ; Eling, TE; Hsi, LC; Wilson, LC, 2003) |
| "The development of colorectal cancer, one of the most frequent cancers, is influenced by prostaglandins and fatty acids." | 1.30 | Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. ( Auwerx, J; Briggs, M; Chen, I; Desreumaux, P; Fruchart, JC; Geboes, K; Heyman, R; Lefebvre, AM; Najib, J, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Noort, V | 1 |
| Schölch, S | 1 |
| Iskar, M | 1 |
| Zeller, G | 1 |
| Ostertag, K | 1 |
| Schweitzer, C | 1 |
| Werner, K | 1 |
| Weitz, J | 1 |
| Koch, M | 1 |
| Bork, P | 1 |
| Schwartz, B | 1 |
| Algamas-Dimantov, A | 1 |
| Hertz, R | 1 |
| Nataf, J | 1 |
| Kerman, A | 1 |
| Peri, I | 1 |
| Bar-Tana, J | 1 |
| Baek, SJ | 1 |
| Wilson, LC | 1 |
| Hsi, LC | 1 |
| Eling, TE | 2 |
| Sabatino, L | 1 |
| Casamassimi, A | 1 |
| Peluso, G | 1 |
| Barone, MV | 1 |
| Capaccio, D | 1 |
| Migliore, C | 1 |
| Bonelli, P | 1 |
| Pedicini, A | 1 |
| Febbraro, A | 1 |
| Ciccodicola, A | 1 |
| Colantuoni, V | 1 |
| Bottone, FG | 1 |
| Moon, Y | 1 |
| Kim, JS | 1 |
| Alston-Mills, B | 1 |
| Ishibashi, M | 1 |
| Seed, B | 1 |
| Lefebvre, AM | 1 |
| Chen, I | 1 |
| Desreumaux, P | 1 |
| Najib, J | 1 |
| Fruchart, JC | 1 |
| Geboes, K | 1 |
| Briggs, M | 1 |
| Heyman, R | 1 |
| Auwerx, J | 1 |
| Sarraf, P | 1 |
| Mueller, E | 1 |
| Smith, WM | 1 |
| Wright, HM | 1 |
| Kum, JB | 1 |
| Aaltonen, LA | 1 |
| de la Chapelle, A | 1 |
| Spiegelman, BM | 1 |
| Eng, C | 1 |
| Kim, JA | 1 |
| Park, KS | 1 |
| Kim, HI | 1 |
| Oh, SY | 1 |
| Ahn, Y | 1 |
| Oh, JW | 1 |
| Choi, KY | 1 |
9 other studies available for troglitazone and Colorectal Cancer
| Article | Year |
|---|---|
Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling.
Topics: Animals; Antineoplastic Agents; Chromans; Citalopram; Colorectal Neoplasms; Gene Expression Profilin | 2014 |
Inhibition of colorectal cancer by targeting hepatocyte nuclear factor-4alpha.
Topics: Animals; Caco-2 Cells; Chromans; Colorectal Neoplasms; Hepatocyte Nuclear Factor 4; HT29 Cells; Huma | 2009 |
Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Division; Chromans; C | 2003 |
A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing.
Topics: Alternative Splicing; Animals; Blotting, Western; Bromodeoxyuridine; Caco-2 Cells; Cell Nucleus; Cel | 2005 |
The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3).
Topics: Activating Transcription Factor 3; Allyl Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2005 |
PPARgamma and colorectal carcinoma: conflicts in a nuclear family.
Topics: Adenomatous Polyposis Coli; Animals; Chromans; Colorectal Neoplasms; Humans; Mice; Receptors, Cytopl | 1998 |
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.
Topics: Adenocarcinoma; Animals; beta Catenin; Chromans; Colorectal Neoplasms; Cyclooxygenase 2; Cytoskeleta | 1998 |
Loss-of-function mutations in PPAR gamma associated with human colon cancer.
Topics: Amino Acid Substitution; Binding Sites; Chromans; Colorectal Neoplasms; Dimerization; DNA-Binding Pr | 1999 |
Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells.
Topics: Blotting, Western; Bromodeoxyuridine; Cell Division; Cell Nucleus; Chromans; Colorectal Neoplasms; C | 2002 |